NGL Fine Chem Ltd
NGL Fine Chem Ltd Q3 FY26 Results & Presentation Highlights: Revenue ₹127.51 Cr, PAT ₹15.69 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on NGL Fine Chem Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Quarterly Revenue (Q3FY26): ₹127.51 crores - Year-on-Year (Y-o-Y) Revenue Growth: 43.11% - Quarterly Revenue (Q3FY25): ₹89.10 crores - Revenue from Operations growth (9MFY26 vs 9MFY2 EBITDA for Q3FY26: ₹22.31 crores, up 338% YoY - EBITDA Margin for Q3FY26: 17.50%, up 1178 basis points YoY - Profit After Tax (PAT) for Q3FY26: ₹15.69 crores, up 1129% YoY - Operating Margin: (EBITDA margin used as proxy, as operating margin not explicitly stated) was 17.50% in Q3FY26 Margin outlook: - Management commentary (Page 6) states operational efficiencies implemented across manufacturing processes are expected to continue strengthening margins over the long term.
From NGL Fine Chem Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Quarterly Revenue (Q3FY26): ₹127.51 crores
- Year-on-Year (Y-o-Y) Revenue Growth: 43.11%
- Quarterly Revenue (Q3FY25): ₹89.10 crores
- Revenue from Operations growth (9MFY26 vs 9MFY25): 28.74% (₹351.89 crores vs ₹273.34 crores)
- Volume drivers: Growth driven primarily by higher volumes across the product portfolio, with price realizations broadly stable (Management commentary on Page 6)
2 more points management made on revenue & sales performance
Profitability & Margins
See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Greenfield Expansion at Tarapur
- Larger capacity expansion to drive next growth leg
- Estimated capex ₹160 crore
- Funded through debt and internal accrual
- Civil construction underway
- Invested ₹156 crore till Q3FY26
- Phase II commissioning scheduled for Q1FY27
- Commercial production expected from H2 FY27 after trial and validation batches
- Total revised investment approx. ₹210 crore
- Subsidiary Macrotech Expansion
- Completed expansion with additional intermediate capacities
- Commercial production started
- Funding
- Borrowings capped at approx. ₹85 crore
- Remaining funding from internal accruals
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
NGL Fine Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem Ltd's management said in earlier quarters
- Q3 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key investor presentation takeaways from Morepen Laboratories Ltd's Q3 FY26 investor presentation — and how it ranks against
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key investor presentation takeaways from Jubilant Pharmova Ltd's Q3 FY26 investor presentation — and how it ranks against sector peers.
- Shree Ganesh Remedies Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹21.11 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY26 investor presentation — and how it rank
- Anuh Pharma Ltd (Q3 FY26)
Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) . Key investor presentation takeaw
Frequently Asked Questions
What were NGL Fine Chem Ltd Q3 FY26 results?
Quarterly Revenue (Q3FY26): ₹127.51 crores - Year-on-Year (Y-o-Y) Revenue Growth: 43.11% - Quarterly Revenue (Q3FY25): ₹89.10 crores - Revenue from Operations growth (9MFY26 vs 9MFY2 EBITDA for Q3FY26: ₹22.31 crores, up 338% YoY - EBITDA Margin for Q3FY26: 17.50%, up 1178 basis points YoY - Profit After Tax (PAT) for Q3FY26: ₹15.69 crores, up 1129% YoY - Operating Margin: (EBITDA margin used as proxy, as operating margin not explicitly stated) was 17.50% in Q3FY26 Margin outlook: - Management commentary (Page 6) states operational efficiencies implemented across manufacturing processes are expected to continue strengthening margins over the long term.
What is NGL Fine Chem Ltd share price analysis?
NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem Ltd planning capital expenditure?
Greenfield Expansion at Tarapur - Larger capacity expansion to drive next growth leg - Estimated capex ₹160 crore - Funded through debt and internal accrual - Civil construction underway - Invested ₹156 crore till Q3FY26 - Phase II commissioning scheduled for Q1FY27 - Commercial production expected from H2 FY27 after trial and validation batches - Total revised investment approx.
Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.